Table 5.
Short term (median 40 days) regression and progression in fasting glucose based glycemic categories between paired baseline data in 2,208 participants with an elevated initial baseline fasting plasma glucose or HbA1c.
| Repeat baseline sample category | |||||
|---|---|---|---|---|---|
| Normal | IFG1b | IFG2b | Type 2 diabetes | Total | |
| Baseline first fasting plasma glucose category | |||||
| Normal (<5.6 mmol/L)a | 392 (69.6%) | 139 (24.7%) | 31 (5.5%) | 1 (0.2%) | 563 |
| Impaired fasting glucose1 (IFG1)b | 121 (27.3%) | 186 (41.9%) | 125 (28.2%) | 12 (2.7%) | 444 |
| Impaired fasting glucose2 (IFG 2)b | 74 (7.8%) | 269 (28.3%) | 494 (52.0%) | 113 (11.9%) | 950 |
| Type 2 diabetesb | 3 (1.2%) | 15 (6.0%) | 80 (31.9%) | 153 (61.0%) | 251 |
aSome participants with normal fasting plasma glucose (<5.6 mmol/L) are included, as they had an elevated HbA1c (6%, ≥42 mmol/mol) on same baseline sample. Please note final total sample size is lower than in Tables 1–3 as repeat sample not undertaken in small number of IFG 2, and a larger population with IFG1 as outlined in methods.
bIFG1 defined as fasting plasma glucose ≥5.6–<6.1 mmol/L, IFG2 defined as fasting plasma glucose ≥6.1–<7.0 mmol/L and Type 2 diabetes defined as fasting plasma glucose ≥7.0 mmol/l11,16.
Median time between paired baseline samples was 40 days (interquartile range 27–69 days).
Data shown as n and % for each row.